Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04731467
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-07
First Post:
2021-01-24
Brief Title:
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Sponsor:
Famewave Ltd
Organization:
Purple Biotech Ltd
Study Overview
Official Title:
A Phase 12 Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors Part A and advanced metastatic pancreatic cancer Parts C D to evaluate the safety and tolerability of CM-24 in combination with nivolumab In Part C of the study gemcitabinenab-paclitaxel or Nal-IRI5-FULV will be administered subsequent to CM24 and nivolumab CM24 nivolumab and gemcitabinenab-paclitaxel or Nal-IRI5-FULV are administered intravenously
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None